Alzheimers Disease Diagnostic Companies

Latest Alzheimers Disease Diagnostic Companies Updates:

Roche Holding AG (Switzerland) Received FDA clearance for its Elecsys Tau and P-tau 181 CSF assays, enabling earlier and more accurate detection of Alzheimer's pathology (Jan 2024).

Lilly and Company (US) Initiated Phase 3 trial for its investigational blood test, PrecivityAD™, to detect Alzheimer's disease through amyloid and tau protein biomarkers (Dec 2023).

C2N Diagnostics (US) Completed successful pilot study of its C2N-Tau blood test for early detection of Alzheimer's disease, demonstrating promising results (Nov 2023).Alzheon Announcing positive Phase 2b data for its investigational tau aggregation inhibitor ALZ-801 for the treatment of early Alzheimer's disease (Jan 2024).

BrainStorm Cell Therapeutics Received FDA Fast Track designation for its NurOwn® stem cell therapy for the treatment of moderate Alzheimer's disease (Dec 2023).

List of Alzheimers Disease Diagnostic Key companies in the market:

• 
  

  Eli Lilly and Company

  
  


• 
  

  TauRx (Republic of Singapore)

  
  


• 
  

  Alector LLC

  
  


• 
  

  Accera, Inc.

  
  


• 
  

  Treventis Corporation

  
  


• 
  

  Neuro-Bio Ltd

  
  


• 
  

  Cognition Therapeutics Inc

  
  


• 
  

  Hoffmann-La Roche

  
  


• 
  

  Novartis AG

  
  


• 
  

  Merck & Co.